GlobeNewswire

Neumora Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
07/05/2026
KOASTAL-2 and -3 studies evaluating navacaprant in major depressive disorder on track for joint topline readout in the second quarter of 2026 Progressing NMRA-511 in Alzheimer’s disease agitation and NMRA-898 in [...]
Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study
07/05/2026
-- Achieved the primary objective with favorable safety and tolerability, no discontinuations and no serious adverse events -- -- Markers of kidney function via eGFR, Cystatin C and magnesium were all within normal [...]
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
07/05/2026
Initial clinical data in SLE and RA for CLN-978, a CD19 T cell engager, to be presented at the EULAR 2026 Congress in June; multi-dose regimen data in RA expected in Q3 2026 Zipalertinib NDA for relapsed EGFR ex20ins [...]
Ligand Reports First Quarter 2026 Financial Results
07/05/2026
First quarter performance driven by strong year-over-year royalty revenue growth of 56% Reaffirms Previously Raised 2026 Full-Year Financial Guidance Reflecting Anticipated Partial-Year Contribution from Pending XOMA [...]
Axsome Therapeutics Recognizes Mental Health Month
07/05/2026
NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced its support [...]
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
07/05/2026
– Decisions on regulatory approval from EMA, UK, and Switzerland for obicetrapib and obicetrapib/ezetimibe fixed - dose combination expected in 2H26, and based on the outcomes, with potential launches by Menarini in [...]
MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant Award
07/05/2026
CARMEL, Ind. and BURLINGTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel [...]
Korro Reports First Quarter 2026 Financial Results and Provides Corporate Update
07/05/2026
Hosted virtual Analyst Day showcasing lead program KRRO-121’s potential to be a first-in-class transformational treatment for hyperammonemia in patients with urea cycle disorders (UCDs) and hepatic encephalopathy (HE); [...]
Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update
07/05/2026
- FHD-909 (LY4050784) Phase 1 dose-escalation trial on track; preclinical combination data with anti-PD-1 antibody demonstrates potential for robust and durable regression with anti-tumor immune memory - Selective CBP [...]
Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update
07/05/2026
Phase 2a follow-up period data for RAP-219 in focal onset seizures (FOS) demonstrated sustained seizure reduction, including a 90% median reduction in clinical seizures over baseline in weeks 9-12 RAP-219 Phase 2 trial [...]
Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
07/05/2026
Interim clinical data from GFORCE-1 trial of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in subjects with elevated CVD risk; readout of expanded GFORCE-1 trial in subjects with elevated CVD risk [...]
Asimov Completes Lead Optimization Campaign with Mabylon AG to Advance Trispecific Antibody for Tree Pollen Allergies
07/05/2026
Mabylon leveraged Asimov’s lead optimization offering, Rapid Pools, to de-risk candidate selection before advancing into cell line development with CHO Edge BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Asimov, the company [...]
Widmer Brothers Launches “Stay Sunny” Campaign, a Full Brand Refresh Across Its Portfolio
07/05/2026
Stay Sunny Brings Renewed Energy to the Historic Oregon Brand Through New Beers, Refreshed Packaging, and a Multichannel Marketing Campaign Rooted in Portland and Extending Across Oregon and the Pacific Northwest [...]
Virbac : Declaration of the number of shares and voting rights 04/2026
07/05/2026
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial [...]
Virbac : Déclaration d'actions et de droits de vote 04/2026
07/05/2026
DECLARATION D’ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d’actions composant le capital (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) [...]
Scarlet Therapeutics Demonstrates In Vivo Survival of Lab-Grown Universal Red Blood Cells Equivalent to Donated Blood
07/05/2026
£3.2M Seed Round Closed to Accelerate Platform Development BRISTOL, United Kingdom, May 07, 2026 (GLOBE NEWSWIRE) -- Scarlet Therapeutics ("Scarlet") today announces a landmark preclinical result: its proprietary cell- [...]
TOMI Environmental Solutions (Nasdaq: TOMZ) Clarifies Previously Announced $120M Preferred Stock LOI to Merge with Carbonium Core, Entering U.S. Nuclear-Grade Graphite Market for Advanced Reactors Within a $13–15B Global Graphite Industry
07/05/2026
Establishes domestic platform in advanced graphite, addressing a multi-billion-dollar end market underpinned by U.S. supply-chain reshoring and next-generation nuclear deployment TOMI Environmental Solutions, Inc. and [...]
ViaNautis Bio to present its targeted polyNaut® nanovesicles (tPNVs) for the generation of in vivo CAR-T therapies at ASGCT Annual Meeting
07/05/2026
Targeted polyNaut® nanovesicles (tPNVs) are ViaNautis’ proprietary, polymer-based delivery platform for oligonucleotides enabling cell ‑ specific targeting through nanobody conjugation CD8 nanobody conjugated tPNVs are [...]
Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease
07/05/2026
The Boards of Directors of Angelini Pharma and Catalyst Pharmaceuticals have unanimously approved the acquisition of Catalyst Pharmaceuticals at 31.50 USD per share in cash, for a total consideration of approximately 4. [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum